The Grover Lab

ABOUT

Our laboratory's research is aimed at identifying novel mechanisms responsible for pathological activation of coagulation and venous thromboembolism. Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is a common cardiovascular disease that is a major source of morbidity and mortality worldwide. The mechanisms that drive pathological activation of coagulation and venous thrombosis remain incompletely understood. We contend that a better understanding of these mechanisms will enable identification of at risk populations and novel targets for the development of safe and effective anticoagulants. We are currently exploring the role of C1-inhibitor, an endogenous inhibitor of multiple intrinsic pathway coagulation factors, as an important negative regulator of coagulation and venous thrombosis.

RESEARCH AREAS

• C1-inhibitor and Venous Thrombosis

• The Intrinsic Pathway in Hemostasis and Thrombosis

NEWS

• 05/11/2023: Our recent publication on C1 inhibitor deficiency and thrombosis has been highlighted in an editorial by David Gailani

• 05/05/2023: Steven Grover presents at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary

• 04/03/2023: The Grover Lab publishes on the association between plasma C1 inhibitor levels and venous thromboembolism  in JTH

• 03/22/2023: Steven Grover presents at the inaugural Immunothrombosis Symposium in Munich, Germany hosted by the LMU Center for Advanced Sciences

• 02/08/2023: The Grover Lab's ASH Plenary highlighted in the Hematologist

• 01/30/2023: Our recent Blood paper has been highlighted in Hematopoiesis News and Rare Disease Advisor

• 01/26/2023: The Grover Lab publishes on enhanced coagulation and venous thrombosis associated with  C1 inhibitor deficiency in mice in Blood

• More